secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001558370-23-001975
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix and Chiesi receive positive CHMP opinion for PRX-102 (pegunigalsidase alfa) for Fabry disease
--------------------------------------------------------------------------------

- CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for adult Fabry disease patients.
- PRX-102 is the first and only pegylated enzyme replacement therapy for Fabry disease.
- Clinical program includes Phase 3 BALANCE, BRIDGE, BRIGHT trials with over 400 years of exposure.
- Final European Commission decision on MAA expected in early May 2023.
- Protalix (PLX) and Chiesi Global Rare Diseases (Chiesi Group) collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023001975/0001558370-23-001975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023001975/plx-20230224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer